AzTrials
AzTrials

Hallux Abducto ValgusPhase 2DYSTANCENCT03569098

Dysport in Hallux Abducto Valgus (HAV) Phase IIa

A Phase 2 study testing Botulinum toxin type A in people with Hallux Abducto Valgus, run by Ipsen at 29 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate the efficacy and safety of treatment with multiple doses of Dysport in adults suffering from clinically significant pain associated with HAV who have not undergone surgery for their condition. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hallux Abducto Valgus
What is being tested?
Botulinum toxin type A
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
186 participants
Where
29 sitesUnited States
Study dates
19 Jun 2018to 22 May 2020
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Clinical diagnosis of HAV
  • Painful HAV in the study foot at Baseline

Who cannot join

  • Flat or square metatarsal head, metatarsus primus elevates, or severe cavus/planus in the study foot
  • Other podiatric or orthopedic condition which would interfere with the evaluation of pain and/or function
  • Medical history or clinical evidence of any vascular disease and/or diabetic condition

Trial locations and contacts

29 sites in 1 country.

29 sites in 1 country

United States29 sites
  • Podiatry 1st

    Belleville, Illinois, 62226

  • Foot and Ankle Center

    Bryn Mawr, Pennsylvania, 19010

  • Center for Clinical Research Inc.

    Castro Valley, California, 94546

  • Weil Foot & Ankle Institute

    Des Plaines, Illinois, 60016

  • Limb Preservation Platform, Inc.

    Fresno, California, 93710

  • Harrisburg Foot and Ankle Center, INC

    Harrisburg, Pennsylvania, 17112

  • Harrisonburg Foot and Ankle Clinic

    Harrisonburg, Virginia, 22801

  • NEA Baptist Clinic

    Jonesboro, Arkansas, 72401

  • Applied Research Center of Arkansas, Inc

    Little Rock, Arkansas, 72212

  • Southwestern Academic Limb Salvage Alliance

    Los Angeles, California, 90033

  • Foot and Ankle Clinic

    Los Angeles, California, 90057

  • Futuro Clinical Trials, LLC

    McAllen, Texas, 78501

  • LCC Medical Research Institute

    Miami, Florida, 33126

  • Rosalind Franklin Clinic

    North Chicago, Illinois, 60064

  • Medical Research International

    Oklahoma City, Oklahoma, 73109

  • Conquest Research

    Orlando, Florida, 32822

  • The Chesapeake Research Group

    Pasadena, Maryland, 21122

  • Martinsville Research Institute, Inc.

    Salem, West Virginia, 24153

  • Summit Foot & Ankle

    Salt Lake City, Utah, 84117

  • Bio X Cell Research

    San Antonio, Texas, 78229

  • University Foot and Ankle Institute

    Santa Monica, California, 90403

  • Doctors Research Network

    South Miami, Florida, 33301

  • Foot and Ankle Center of Illinois

    Springfield, Illinois, 62704

  • Dr. Allen M. Jacobs and Associates

    St Louis, Missouri, 63117

  • 1Foot 2Foot Centre for Foot and Ankle Care, PC

    Suffolk, Virginia, 23434

  • Center for Spine and Orthopedics

    Thornton, Colorado, 80229

  • Texas Gulf Coast Medical Group

    Webster, Texas, 77598

  • Clinical Research

    West Palm Beach, Florida, 33406

  • Ankle and Foot Care Centers

    Youngstown, Ohio, 22801

Other trials in United States

About this study

Official title: A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus

The purpose of this study is to investigate the efficacy and safety of treatment with multiple doses of Dysport in adults suffering from clinically significant pain associated with HAV who have not undergone surgery for their condition.

Being tested
Botulinum toxin type A, Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Botulinum toxin type ABiological

    Also called AbobotulinumtoxinA (Dysport®), Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC)

    Investigators will inject the reconstituted solution into foot muscles.

  • PlaceboDrug

    Investigators will inject the reconstituted solution into foot muscles.

Study groups in NCT03569098
Study groupRoleWhat they receive
Dysport Dose 1ExperimentalIntramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
Receives: Biological: Botulinum toxin type A
Dysport Dose 2ExperimentalIntramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
Receives: Biological: Botulinum toxin type A
PlaceboPlacebo comparatorIntramuscular injection of Placebo on day 1 of cycle 1 (double-blind period)
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Least Square (LS) Mean Change From Baseline in the Daily Numeric Pain Rating Scale (NPRS) Score at Week 8

    The NPRS is a widely used and validated unidimensional measure of pain intensity in adults. Participants were asked to rate the intensity of their foot pain during physical activity (example, walking, standing or running) based on an 11-point scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "worst possible pain". Higher scores indicate a worse outcome. Daily pain intensities were recorded by the participant using an electronic diary (eDiary) for 7 consecutive days prior to each study visit. Baseline was defined as the daily NPRS score averaged over the 7 consecutive days prior to the Baseline visit (Day 1).

    Measured: Baseline and Week 8 in the double-blind treatment period

Secondary outcomes (13)
  1. LS Mean Change From Baseline in the Daily NPRS Score at Weeks 4 and 12

    The NPRS is a widely used and validated unidimensional measure of pain intensity in adults. Participants were asked to rate the intensity of their foot pain during physical activity (example, walking, standing or running) based on an 11-point scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "worst possible pain". Higher scores indicate a worse outcome. Daily pain intensities were recorded by the participant using an eDiary for 7 consecutive days prior to each study visit. Baseline was defined as the daily NPRS score averaged over the 7 consecutive days prior to the Baseline visit (Day 1).

    Measured: Baseline and Weeks 4 and 12 in the double-blind treatment period

  2. LS Mean Change From Baseline in the Daily Modified Foot Function Index (mFFI) Disability Subscale Score at Weeks 4, 8 and 12

    The foot function index (FFI) was developed to assess foot-related pain, disability and activity limitations and later revised to include foot-related health and quality of life. A modified version of FFI specific to this study was used. The mFFI consists of a total of 21 items grouped into 3 subscales: pain (7 questions), disability (9 questions) and activity limitation (5 questions). The mFFI disability subscale is rated using numeric rating scale ranging from 0 to 10, where 0 represents "no difficulty" and 10 represents "so difficult unable to do". For each item, the participant was asked to record the number value which best corresponded to effect of the foot complaints. To obtain a subscale score, the item scores for a given subscale (i.e., pain, disability or activity limitation subscales) were totaled and divided by maximum total possible and then multiplied by 100. Each subscale score, as well as the total score, ranged from 0 to 100. Higher scores indicate a worse outcome.

    Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period

  3. LS Mean Change From Baseline in the Daily mFFI Pain Subscale Score at Weeks 4, 8 and 12

    The FFI was developed to assess foot-related pain, disability and activity limitations and later revised to include foot-related health and quality of life. A modified version of the FFI specific to this study was used. The mFFI consists of a total of 21 items grouped into 3 subscales: pain (7 questions), disability (9 questions) and activity limitation (5 questions). The mFFI pain subscale is rated using numeric rating scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "worst pain imaginable". For each item, the participant was asked to record the number value which best corresponded to the effect of the foot complaints. To obtain a subscale score, the item scores for a given subscale (i.e., pain, disability or activity limitation subscales) were totaled and divided by the maximum total possible and then multiplied by 100. Each subscale score, as well as the total score, ranged from 0 to 100. Higher scores indicate a worse outcome.

    Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period

  4. LS Mean Change From Baseline in the Daily mFFI Total Score at Weeks 4, 8 and 12

    The FFI was developed to assess foot-related pain, disability and activity limitations and later revised to include foot-related health and quality of life. A modified version of the FFI specific to this study was used. The mFFI consists of a total of 21 items grouped into three subscales: pain (7 questions), disability (9 questions) and activity limitation (5 questions). The mFFI items are rated using numeric rating scales ranging from 0 to 10, where 0 represents "no pain/no difficulty/none of the time" and 10 represents "worst pain imaginable/so difficult unable to do/all of the time" for pain, disability and activity limitation subscales, respectively. For each item, the participant was asked to record the number value which best corresponded to the effect of the foot complaints. To obtain a total score, the scores of all 3 subscales were totaled and divided by 3. Each subscale score, as well as the total score, ranged from 0 to 100. Higher scores indicate a worse outcome.

    Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period

  5. LS Mean Change From Baseline in the Daily mFFI Activity Limitation Subscale Score at Weeks 4, 8 and 12

    The FFI was developed to assess foot-related pain, disability and activity limitations and later revised to include foot-related health and quality of life. A modified version of the FFI specific to this study was used. The mFFI consists of a total of 21 items grouped into 3 subscales: pain (7 questions), disability (9 questions) and activity limitation (5 questions). The mFFI activity limitation subscale is rated using numeric rating scale ranging from 0 to 10, where 0 represents "none of the time" and 10 represents "all of the time". For each item, the participant was asked to record the number value which best corresponded to the effect of the foot complaints. To obtain a subscale score, the item scores for a given subscale (i.e., pain, disability or activity limitation subscales) were totaled and divided by the maximum total possible and then multiplied by 100. Each subscale score, as well as the total score, ranged from 0 to 100. Higher scores indicate a worse outcome.

    Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period

  6. LS Mean Change From Baseline in HV Angle at Weeks 4, 8 and 12

    The HV angle was measured directly on weight-bearing anteriorposterior radiographs, in which the X-ray beam was angled 15° towards the heel centered on the second tarsometatarsal joint with a source to image-receptor distance of 100 centimeters (cm).

    Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period

  7. LS Mean Change From Baseline in Intermetatarsal Angle at Weeks 4, 8 and 12

    The intermetatarsal angle was measured directly on weight-bearing anteriorposterior radiographs, in which the X-ray beam was angled 15° towards the heel centered on the second tarsometatarsal joint with a source to image-receptor distance of 100 cm.

    Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period

  8. Median Time to Retreatment

    Time to retreatment was calculated as ([Date of retreatment - previous injection date] + 1) / 7 (week). Time to retreatment was calculated for each cycle and the data presented here for the double-blind treatment period.

    Measured: Up to 24 weeks in the double-blind treatment period

  9. LS Mean Change From Baseline in Patient Global Impression of Severity (PGI-S) of Foot Pain Score at Weeks 4, 8 and 12

    An assessment of PGI-S of foot pain was conducted by the participant using a 4-point Likert scale ranging from 0= no pain to 3= severe pain. Higher scores indicate a worse outcome. The PGI-S was assessed by the participant by answering the following question: "How severe was your foot pain while performing physical activities (example, standing, walking or running) over the past week?" (0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain).

    Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period

  10. LS Mean Change From Baseline in PGI-S of Disability Score at Weeks 4, 8 and 12

    An assessment of PGI-S of disability was conducted by the participant using a 4-point Likert scale ranging from 0= no disability to 3= severe disability. Higher scores indicate a worse outcome. The PGI-S was assessed by the participant by answering the following question: "How severe was your disability while performing physical activities (example, standing, walking or running) over the past week?" (0=no disability; 1=mild disability; 2=moderate disability; 3=severe disability).

    Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period

  11. LS Mean Patient Global Impression of Improvement (PGI-I) of Foot Pain Score at Weeks 4, 8 and 12

    An assessment of PGI-I of foot pain was conducted by the participant using a 7-point Likert scale ranging from -3= very much worse to +3= very much improved. Higher scores indicate a better outcome. The PGI-I was assessed by the participant answering the following question: "Compared to your foot pain prior to the study treatment initiation, your foot pain while performing physical activities (example, standing, walking or running) now is: +3=very much improved; +2=much improved; +1=minimally improved; 0=no change; -1=minimally worse; -2=much worse; -3=very much worse".

    Measured: Weeks 4, 8 and 12 in the double-blind treatment period

  12. LS Mean PGI-I of Disability Score at Weeks 4, 8 and 12

    An assessment of PGI-I of the participant's disability was conducted by the participant using a 7-point Likert scale ranging from -3= very much worse to +3= very much improved. Higher scores indicate a better outcome. The PGI-I was assessed by the participant answering the following question: "Compared to your disability prior to the study treatment initiation, your disability while performing physical activities (example, standing, walking or running) now is: +3=very much improved; +2=much improved; +1=minimally improved; 0=no change; -1=minimally worse; -2=much worse; -3=very much worse".

    Measured: Weeks 4, 8 and 12 in the double-blind treatment period

  13. Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score at Weeks 8 and 12

    The SF-36 is a 36-item questionnaire which measures the extent to which physical health impacts an individual's functional ability and perceived wellbeing in mental, social, and physical aspects of life. The SF-36 has 8 subscales: physical function, role physical, bodily pain, global health, vitality, social function, role emotional and mental health. Each scale ranges from 0-100, where 0= lowest level of health and 100= highest level of health. Scores on these subscales can be aggregated into the physical component summary (physical function, role physical, bodily pain and global health) and mental component summary (mental health, vitality, social function and role emotional). Physical component summary score ranges from 0.65 to 80.73 and mental component summary score ranges from -8.81 to 81.65, where low score indicates lowest level of health and high score indicates highest level of health. Positive change from Baseline indicates an improvement in quality of life.

    Measured: Baseline and Weeks 8 and 12 in the double-blind treatment period

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jun 2018
  2. Study start19 Jun 2018
  3. Primary completion17 Dec 2019
  4. Study completion22 May 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
186 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03569098
Sponsor's protocol ID
D-FR-52120-237
Acronym
DYSTANCE
Status last verified
Jul 2021
First submitted
14 Jun 2018
Last updated
2 Jul 2021
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Botulinum toxin type A in people with Hallux Abducto Valgus, run by Ipsen at 29 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 29 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Jul 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Least Square (LS) Mean Change From Baseline in the Daily Numeric Pain Rating Scale (NPRS) Score at Week 8 (time frame: Baseline and Week 8 in the double-blind treatment period). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in